Dr. Kurt Wolff GmbH & Co. KG   Report issue

For profit
Founded: Bielefeld Germany (1908)
Status: No NME R&D (1908)

Organization Overview

First Clinical Trial
2018
NCT03681340
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Dr. Joachim Enax | Dr. Kurt Wolff GmbH & Co. KG

Active Ingredients

Drugs in Other Trials (2)

hydroxyapatite silica (2 trials)

sodium fluoride (18F) (2 trials)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 2
  • # of Trial APIs: 2